LEXEO THERAPEUTICS INC (LXEO)

US52886X1072 - Common Stock

6.28  +0.24 (+3.97%)

After market: 6.28 0 (0%)

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (12/20/2024, 8:23:14 PM)

After market: 6.28 0 (0%)

6.28

+0.24 (+3.97%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
CRS4.68
6 Month-61.23%
Overview
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Ins Owners0.42%
Inst Owners91.47%
Market Cap207.68M
Shares33.07M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts86.15
Short Float %6.99%
Short Ratio5.11
IPO11-03 2023-11-03
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LXEO Daily chart

Company Profile

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 58 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Company Info

LEXEO THERAPEUTICS INC

345 Park Avenue South, Floor 6

New York City NEW YORK

P: 12125479879

Employees: 69

Website: https://www.lexeotx.com/

LXEO News

News Image4 days ago - Lexeo TherapeuticsLexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer...

News Imagea month ago - Market News VideoLexeo Therapeutics Becomes Oversold (LXEO)
News Imagea month ago - Lexeo TherapeuticsLexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results...

News Image2 months ago - Lexeo TherapeuticsLexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's...

News Image2 months ago - Lexeo TherapeuticsLexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference...

News Image3 months ago - Market News VideoLexeo Therapeutics Becomes Oversold (LXEO)

LXEO Twits

Here you can normally see the latest stock twits on LXEO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example